A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...

Some online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

Gemma Collins says she was shocked by how her face changed after losing two stone on Mounjaro. Experts warn of a side effect ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Health insurance companies, including CVS Caremark, are altering coverage for GLP-1 weight loss medications like Zepbound, ...